The University of Tokyo · 의학
Kotaro Sugawara 교수의 연구실은 소견암 및 식도암 치료의 새로운 전략을 모색하는 데 초점을 맞추고 있습니다. 특히 온콜리틱 바이러스 치료와 면역검사지점 억제제의 조합요법을 통해 종양 미세환경을 재편하고 면역 반응을 강화하는 데 기여하고 있으며, 영양 상태 및 염증 지표를 활용한 예후 예측 모델 개발에도 주력하고 있습니다. 이는 환자의 생존 기간을 정밀하게 예측하고, 수술적 재발 치료의 적응 여부를 보다 정교하게 평가하는 데 기여합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Oncolytic virus therapy can increase the immunogenicity of tumors and remodel the immunosuppressive tumor microenvironment, leading to an increased antitumor response to immune-checkpoint inhibitors. Here, we investigated the therapeutic potential of G47Δ, a third-generation oncolytic herpes simplex virus type 1, in combination with immune-checkpoint inhibitors using various syngeneic murine subcutaneous tumor models. Intratumoral inoculations with G47Δ and systemic anti-cytotoxic T-lymphocyte-a
GNRI is useful for predicting survival and oncological outcomes in GC patients.
Various inflammatory or nutritional markers, especially those derived from CRP, are useful for predicting survival outcomes of ESCC patients. The predictive capabilities of these indices were augmented when used in combination with pStage.
Salvage esophagectomy (SALV) is potentially beneficial for patients with residual or relapsed esophageal carcinoma after definitive chemoradiotherapy (dCRT), although preoperatively identifying good candidates for SALV remains difficult. We investigated the prognostic impacts of inflammatory and nutritional status in patients undergoing SALV after dCRT. Forty-seven SALV patients were retrospectively reviewed, of whom 46 (98%) had squamous cell carcinoma and 1 (2%) adenocarcinoma. Possible progno
The survival outcomes of patients with relapsed EC remain poor. Surgical treatments could provide survival benefits for patients with recurrent EC, especially for patients with OM.
